Loading…
← CockpitCompetitor Analysis › 1513.HK Livzon Pharmaceutical Group Inc Class HOpen in the cockpit ↗

Livzon Pharmaceutical Group Inc Class H1513.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Chinese pharmaceutical group making generic and biologic drugs plus in-vitro diagnostic reagents.

≈ A diversified Chinese generics + diagnostics makerMomentum leader 82
Mkt cap
$3.73B
US dollars, full cap
Free float
45%
of shares outstanding
$/day
$4.51M
20-day average traded
Fwd P/E
11.3×
forward earnings
ROIC−WACC
+9.1 pp
WACC 7.2%
Hurdle
-9 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · HKDHK$24.98
1D0.0%
1W+1.5%
1M+17.8%
3M-0.4%
6M-8.6%
YTD-12.4%
1Y-22.9%
ATR %2.8%
52w lowhigh24.7% off high

What Livzon Pharmaceutical does

Chinese pharmaceutical group making generic and biologic drugs plus in-vitro diagnostic reagents.

Sells medicines and diagnostic kits mainly in China, where hospital purchasing rules press prices on older generics and test kits depend on lab volume. This is the Hong Kong share class of the same group as 000513.SZ, controlled by Joincare Pharmaceutical, a listed Chinese drug group.

In one line: A diversified Chinese generics + diagnostics maker.

Products and services

  • Generic drugs
  • Biologics (e.g. thyroid hormones)
  • Diagnostic reagents/kits
  • Vaccines

Customers

  • Hospitals
  • Diagnostic labs in China

Where it sits in the supply chain

  • Pharmaceuticals
  • Generic & biologic drugs
  • In-vitro diagnostics

What could go right

  • Diagnostics demand growth in China

What could go wrong

  • Centralized procurement price cuts

Moat: narrow (scale, regulatory licence). Broad approved-product portfolio across drugs and diagnostics gives scale advantages.

Headquarters: Zhuhai, China · Founded: 1985 · Employees: 8,878

Named competitors

Livzon Pharmaceutical at a glance

Size Livzon Pharmaceutical (1513.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $3.73B, the 294th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$24.98 on 18 Nov 2026.

Performance Over six months the shares fell 8.6%, against +5.7% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 6th lowest of 19 in its peer set.

Growth Revenue fell 9.6% over the last twelve months (peer median +13.9%); the operating margin is 19.3% (peer median 15.7%).

Valuation It trades at 11.3× forward earnings against a peer median of 20.1× (3rd cheapest of 12).

Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -9 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 9.1 points above its cost of capital (7.2% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 1071513.HK 90
Six months, rebased to 100: Livzon Pharmaceutical against the median of its 20 peers (local-currency closes).

Livzon Pharmaceutical financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$11.6BHK$12.9BHK$12.7BHK$13.6BHK$14.6B
Revenue growth—+2%-7%-7%—
Gross profitHK$7.48BHK$8.28BHK$8.07BHK$8.17BHK$9.01B
EBITDAn/aHK$3.45BHK$3.44BHK$3.08BHK$3.02B
Net incomeHK$1.77BHK$2.19BHK$2.23BHK$2.16BHK$2.22B
Free cash flowHK$3.19BHK$2.83BHK$2.63BHK$2.84BHK$2.28B
Capital expenditureHK$476MHK$623MHK$618MHK$907MHK$1.09B
Total debtHK$4.92BHK$4.28BHK$5.27BHK$5.54BHK$5.19B

Quarterly statements and history in the cockpit →

Livzon Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-25%0%+25%+50%TARSXENEROVI600329SLSOGN6883363320WOCKPHARMA128940SFZNACUTAAS1877ARQTDFTXAMLX1513.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Livzon Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×20×40×60×ROVI600329OGN6883366005213320128940ACUTAASARQT1513.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Livzon Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%TARSROVI600329OGN688336301569WOCKPHARMAARQT1513.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Livzon Pharmaceutical is the large dot.

Livzon Pharmaceutical competitors and peer comparison

Head to head with its named competitors (1513.HK vs 3320.HK vs 2096.HK vs 1099.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Livzon Pharmaceutical 1513.HK$3.73B-9%-10%19%11.3×-7.0%
China Resources Pharmaceutical 3320.HK$3.60B-7%+8%4%5.8×-4.9%
Simcere Pharmaceutical 2096.HK$3.42B-5%+27%18%13.5×-3.4%
Sinopharm 1099.HK$6.74B0%+3%3%6.2×-7.3%

How Livzon Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Livzon Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure1513.HKPeer medianRank in peer set
1-month return+17.8%-0.2%3rd highest of 21
6-month return-8.6%+5.7%6th lowest of 19
Distance from 52-week high-24.7%-26.4%10th highest of 21
Revenue growth (TTM)-9.6%+13.9%3rd lowest of 18
Operating margin19.3%15.7%7th highest of 16
Forward P/E11.3×20.1×3rd cheapest of 12
Growth the price implies (Req g, 7 yrs)-7.0%5.5%least demanding of 13
Growth delivered (Del g)+2.0%+7.7%3rd lowest of 13
Hurdle (Req g minus delivered)-9.0 pp-7.0 pp7th least demanding of 13
ROIC minus cost of capital+9.1 pp+4.6 pp6th highest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Livzon Pharmaceutical 1513.HKHong Kong$3.73B-9%-10%19%11.3×-7.0%+2.0%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%n/a34.7%+159.5%
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%21.9×1.2%+12.1%
Tianjin Pharmaceutical Da Ren Tang 600329.SSChina$3.75B-10%-13%20%28.5×16.2%-5.8%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%39.9×0.9%+45.1%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%n/a57.4%+3.1%
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%n/a58.0%+4.2%
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%15.0×4.7%+7.5%
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%16.8×n/an/a
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%n/an/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
Amylyx Pharmaceuticals AMLXUnited States$3.42B+93%+100%n/an/an/an/a

Questions

Who are Livzon Pharmaceutical's main competitors?
Named competitors: China Resources Pharmaceutical (3320.HK), Simcere Pharmaceutical (2096.HK), Sinopharm (1099.HK). The cockpit's measured peer set (industry) also includes Tarsus Pharmaceuticals (TARS), Xenon Pharmaceuticals (XENE), Laboratorios Farmaceuticos Rovi (ROVI.MC), Tianjin Pharmaceutical Da Ren Tang (600329.SS), SELLAS Life Sciences (SLS), Organon & (OGN).
Is Livzon Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 11.3× against a peer median of 20.1×, 3rd cheapest of 12 in its peer set. For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -9 pp: the price already allows for a slowdown.
How has Livzon Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -8.6% against +5.7% for the median peer; over one year -22.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.